Form 4: Director Vicky Gregg Increases Stake in Quest Diagnostics

Quest Diagnostics Director Vicky B. Gregg acquired 68 shares of common stock through a dividend reinvestment plan.

Summary

• Director Vicky B. Gregg acquired 68 shares of Quest Diagnostics (DGX) common stock.
• The transaction occurred on April 20, 2026, at a price of $194.698 per share.
• Following this transaction, the director's total beneficial ownership is 17,172 shares.
• The acquisition was executed via a dividend reinvestment plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the acquisition is a routine dividend reinvestment rather than an open-market purchase.

Positives

• Director demonstrates continued commitment to the company through increased equity ownership.

Negatives

• None.

Risks

• None.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that routine dividend reinvestment by board members is a standard corporate governance activity and does not typically signal a change in strategic direction or material non-public information.

Comparison to Industry Standards

• The transaction is consistent with standard director equity participation programs observed in large-cap healthcare companies.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine administrative transaction.

Next Steps

• None.

Key Dates

Keywords

Quest Diagnostics, DGX, Form 4, Insider Trading, Dividend Reinvestment, Director Ownership